|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, intratumoral injection of ANO1 siRNA suppressed subcutaneous xenograft tumor growth in nude mice implanted with ovarian cancer SKOV3 cells.
|
30243029 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, Ano1 depletion failed to affect tumor development in a model of colorectal cancer.
|
31383845 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Based on c-kit and DOG-1 immunoreactivity and a PDGFRA mutation (p.Trp559_Arg560del), the tumor was diagnosed as an epithelioid variant GIST.
|
31273885 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nodule was resected in an enucleation procedure; subsequent histopathologic examination revealed a low-grade, spindled cell neoplasm with diffuse immunoreactivity for CD117 (cKit) and DOG1, diagnostic of GIST.
|
31497448 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor showed variable staining in the 2 components with diffuse DOG-1 and CD117 positivity in the WD component and complete absence in the DD foci.
|
31072206 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ANO1 expression was associated with advanced tumor stage and lymph node metastasis, and there was an inverse relationship between miR-9 and ANO1 mRNA expression in CRC specimens, but no significant difference was found between miR-9 and ANO1 expression.
|
30803553 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DOG1 is a calcium-activated chloride channel that has gained attention as a promising drug target due to its involvement in several processes essential for tumor development and progression.
|
31262867 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that there was a significant difference between the two groups in tumor size (P < 0.001), histological type (P = 0.013), CD34 expression (P < 0.001), and DOG-1 expression (P < 0.001).
|
30445975 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical investigation of the tumour located in the mesentery showed that the staining for the S-100 protein was strongly positive, while the stainings of SMA, CD34, CD117 and DOG-1 were negative.
|
29375216 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, silencing of ANO1 inhibits growth of PC-3 xenograft tumors in nude mice and induces apoptosis in tumors via upregulation of TNF-α signaling.
|
29899325 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, this study demonstrates that ANO1 expression is an indicator of poor prognosis of breast carcinoma patients and suggests that ANO1 might be a therapeutic target for breast carcinoma patients with ANO1-positive tumors and poor prognosis.
|
29416639 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alterations in the expression of I<sup>-</sup> transporters are associated with tumor development in a cancer-type-dependent manner and, accordingly, NIS, CFTR and ANO1 have been proposed as tumor markers.
|
29437784 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a calcium-activated chloride channel expressed widely mammalian cells, including epithelia, vascular smooth muscle tissue, electrically excitable cells, and some tumors.
|
28493701 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANO1 has been demonstrated to be critical for tumor growth in breast and head and neck cancers through its regulation of EGFR signaling and pathway modulators like MAPK and protein kinase B.
|
28293832 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DOG1 expression in tumors showed low sensitivity and specificity for skin adnexal origin.
|
28394798 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-381 may function as a tumor suppressor by directly targeting TMEM16A and regulating TGF-β pathway and EMT process in the development of progression of gastric cancer.
|
28193228 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study investigated this using a multimodal, translational investigation.<b>Experimental Design:</b> Combination of (i) <i>in vitro</i> HNSCC cell culture experiments assessing cell viability, apoptotic activation, and protein expression (ii) <i>in vivo</i> studies assessing similar outcomes, and (iii) molecular and staining analysis of human HNSCC samples.<b>Results:</b> TMEM16A expression was found to correlate with greater tumor size, increased Erk 1/2 activity, less Bim expression, and less apoptotic activity overall in human HNSCC.
|
28899969 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery.
|
28299581 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative PCR was used to explore copy number gains of specific genes (3q-PIK3CA, TP63; 11q13.3-CCND1, ANO1) in tumor DNA recovered from HPSCC (n = 48) and OPSCC (n = 52) patients.
|
27750372 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TMEM16A, a Ca<sup>2+</sup> -activated Cl<sup>-</sup> channel, contributes to tumor growth in breast cancer and head and neck squamous cell carcinoma (HNSCC).
|
28177558 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DOG1 was expressed in 66% of CD117(+) GISTs and highly associated with tumor size and the rate of wild-type tumors.
|
26867653 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor size, mitotic count and risk level were associated with ANO1 detection in resectable GIST patients.
|
27153560 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that ANO1 knockdown significantly inhibited cell proliferation and induced cell apoptosis in either tumor cell lines or normal HaCaT cell line.
|
27732935 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA.
|
25766843 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DNA from tumor tissues and normal adjacent tissues was isolated and amplified for the 22 exons of PDGFRA and 26 exons of DOG1.Each PCR product was sequenced.
|
26191287 |
2015 |